SEC 13F Intelligence

Managers / Q1 2021 · view latest →

Corriente Advisors, LLC

CIK 0001406718 · 1401 FOCH ST, SUITE 100, FORT WORTH, TX, 76107 · 8178700400

Reported Value
$272M
Q1 2021
Positions
10
Filings on Record
17
2020–present window
Filed
May 18, 2021
original filing

Summary

Corriente Advisors, LLC reported $272M in U.S.-listed holdings across 10 positions for Q1 2021.

The portfolio is heavily concentrated: Maxar Technologies alone accounts for 36.9% of reported value.

Compared with Q4 2020, the fund opened 4 new positions and exited 13.

Portfolio Metrics

Turnover
+18.9%
vs prior filed quarter
Top-10 Concentration
+100.0%
share of reported value
Largest Position
+36.9%
Maxar Technologies
New / Exited
4 / 13
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’19: $186MQ4 ’19Q1 ’20: $93MQ2 ’20: $154MQ2 ’20Q3 ’20: $197MQ4 ’20: $420MQ4 ’20Q1 ’21: $272MQ2 ’21: $185MQ2 ’21Q3 ’21: $52MQ4 ’21: $12MQ4 ’21Q1 ’22: $268MQ2 ’22: $237MQ2 ’22Q3 ’22: $90MQ4 ’22: $0Q4 ’22Q1 ’23: $976,400Q2 ’23: $10,872Q2 ’23Q4 ’23: $10Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 100.0%
  • Common Stock · 100.0% · $272M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
TDYTELEDYNE TECHNOLOGIES INCNEW+55.0K55.0K+$23M$23M
METAFACEBOOK INCNEW+50.0K50.0K+$15M$15M
LTRNLANTERN PHARMA INCNEW+713.8K713.8K+$13M$13M
EYPTEYEPOINT PHARMACEUTICALS INCNEW+200.0K200.0K+$2M$2M
REATA PHARMACEUTICALS INCSOLD OUT−525.0K0−$65M$0
CCJCAMECO CORPSOLD OUT−2.18M0−$29M$0
GPROGOPRO INCSOLD OUT−3.35M0−$28M$0
FIREEYE INCSOLD OUT−690.0K0−$16M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2021

10 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MAXAR TECHNOLOGIES INCCOM36.90%$100M2.65M
2REPLREPLIMUNE GROUP INChistory →COM12.08%$33M1.07M
3CUE BIOPHARMA INCCOM11.45%$31M2.55M
4CRDFCARDIFF ONCOLOGY INChistory →COM9.50%$26M2.79M
5TDYTELEDYNE TECHNOLOGIES INChistory →COM8.38%$23M55.0K
6TFF PHARMACEUTICALS INCCOM7.82%$21M1.57M
7METAFACEBOOK INChistory →CL A5.42%$15M50.0K
8LTRNLANTERN PHARMA INChistory →COM4.77%$13M713.8K
9DMACDIAMEDICA THERAPEUTICS INChistory →COM NEW2.93%$8M870.2K
10EYPTEYEPOINT PHARMACEUTICALS INCCOM NEW0.75%$2M200.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2023$10M3Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review7Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$10,8722Aug 9, 202313F-HRchanges · EDGAR ↗
Q1 2023$976,4002May 10, 202313F-HRchanges · EDGAR ↗
Q4 2022$01Feb 15, 202313F-HRchanges · EDGAR ↗
Q3 2022$90M5Nov 15, 202213F-HRchanges · EDGAR ↗
Q2 2022$237M5Aug 16, 202213F-HRchanges · EDGAR ↗
Q1 2022$268M5May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$12M3Feb 15, 202213F-HRchanges · EDGAR ↗
Q3 2021$52M8Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$185M15Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$272M10May 18, 202113F-HRchanges · EDGAR ↗
Q4 2020$420M19Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$197M16Nov 3, 202013F-HRchanges · EDGAR ↗
Q2 2020$154M16Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$93M11May 18, 202013F-HRchanges · EDGAR ↗
Q4 2019$186M17Feb 14, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.